Fused Bicyclic Orexin-2 Agonists for CNS Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds with orexin-2 receptor agonist activity are not satisfactory in terms of activity, pharmacokinetics, permeability into the brain/central nervous system, or safety, necessitating the development of improved compounds for treating conditions like narcolepsy and other disorders.
Innovation Solution
Development of fused bicyclic compounds represented by Formula I-A or their pharmaceutically acceptable salts, which act as orexin-2 receptor agonists, featuring specific ring structures and substituents to enhance activity and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds with orexin-2 receptor agonist activity are used, then therapeutic effect is achieved, but activity and safety profiles are not satisfactory
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of orexin-2 receptor agonists through specific fused bicyclic core structures (Formula I-A) with varied substituents (R1-R9 groups). These structural parameter changes optimize both therapeutic activity and safety profile by adjusting molecular properties such as lipophilicity, steric bulk, and electronic distribution to improve selectivity and reduce off-target effects.
Solution Approach 2:
The patent employs composite material principles by creating complex fused bicyclic molecular structures that combine multiple functional groups and ring systems. The compounds integrate heterocyclic rings, aromatic systems, and various substituent patterns to achieve enhanced receptor binding affinity and improved pharmacokinetic properties, resulting in superior therapeutic profiles compared to single-structure analogs.
2Reliability
If existing orexin-2 receptor agonist compounds are used, then wakefulness maintenance is achieved, but permeability into the brain/central nervous system is insufficient
Solution Approach 1:
The patent optimizes brain permeability by adjusting molecular parameters of the fused bicyclic compounds, including controlling molecular weight, optimizing lipophilicity through substituent selection, and modifying structural flexibility. These parameter adjustments enhance the compounds' ability to cross the blood-brain barrier while maintaining orexin-2 receptor agonist activity, ensuring adequate CNS penetration for therapeutic effect.
3Reliability
If existing orexin-2 receptor agonist compounds are used, then therapeutic activity is achieved, but pharmacokinetics are not satisfactory
Solution Approach 1:
The patent improves pharmacokinetic profile by modifying structural parameters of the fused bicyclic core and its substituents to optimize absorption, distribution, metabolism, and excretion properties. Variations in ring substitution patterns, heteroatom content, and side chain characteristics are tuned to achieve appropriate half-life, bioavailability, and metabolic stability, thereby enhancing overall therapeutic activity and duration of action.
Data Source
AI summary
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.